B H Kushner

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. doi request reprint Posterior reversible encephalopathy syndrome in neuroblastoma patients receiving anti-GD2 3F8 monoclonal antibody
    Brian H Kushner
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Cancer 119:2789-95. 2013
  2. ncbi request reprint 5-day/5-drug myeloablative outpatient regimen for resistant neuroblastoma
    B H Kushner
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Bone Marrow Transplant 48:642-5. 2013
  3. doi request reprint Ifosfamide, carboplatin, and etoposide for neuroblastoma: a high-dose salvage regimen and review of the literature
    Brian H Kushner
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Cancer 119:665-71. 2013
  4. ncbi request reprint Reduction from seven to five cycles of intensive induction chemotherapy in children with high-risk neuroblastoma
    Brian H Kushner
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    J Clin Oncol 22:4888-92. 2004
  5. ncbi request reprint A focal lesion in the falx cerebri: Harbinger of classic stage 4 neuroblastoma in an infant cured despite residual disease after minimal therapy
    Brian H Kushner
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Pediatr Blood Cancer 53:1340-2. 2009
  6. ncbi request reprint Camptothecin analogs (irinotecan or topotecan) plus high-dose cyclophosphamide as preparative regimens for antibody-based immunotherapy in resistant neuroblastoma
    Brian H Kushner
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Clin Cancer Res 10:84-7. 2004
  7. ncbi request reprint Neuroblastoma in adolescents and adults: the Memorial Sloan-Kettering experience
    Brian H Kushner
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Med Pediatr Oncol 41:508-15. 2003
  8. doi request reprint Differential impact of high-dose cyclophosphamide, topotecan, and vincristine in clinical subsets of patients with chemoresistant neuroblastoma
    Brian H Kushner
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Cancer 116:3054-60. 2010
  9. ncbi request reprint Curability of recurrent disseminated disease after surgery alone for local-regional neuroblastoma using intensive chemotherapy and anti-G(D2) immunotherapy
    Brian H Kushner
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    J Pediatr Hematol Oncol 25:515-9. 2003
  10. ncbi request reprint Tumor lysis syndrome, neuroblastoma, and correlation between serum lactate dehydrogenase levels and MYCN-amplification
    Brian H Kushner
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, New York 10021, USA
    Med Pediatr Oncol 41:80-2. 2003

Detail Information

Publications75

  1. doi request reprint Posterior reversible encephalopathy syndrome in neuroblastoma patients receiving anti-GD2 3F8 monoclonal antibody
    Brian H Kushner
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Cancer 119:2789-95. 2013
    ..In this report, the authors describe PRES associated with antidisialoganglioside (anti-GD2 ) monoclonal antibody (MoAb) immunotherapy, which is now standard for high-risk neuroblastoma but has not previously been implicated in PRES...
  2. ncbi request reprint 5-day/5-drug myeloablative outpatient regimen for resistant neuroblastoma
    B H Kushner
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Bone Marrow Transplant 48:642-5. 2013
    ..In conclusion, 5D/5D (including HSCT) spares vital organs, entails modest morbidity, shows activity against resistant NB and helps patients meet eligibility requirements for formal clinical trials...
  3. doi request reprint Ifosfamide, carboplatin, and etoposide for neuroblastoma: a high-dose salvage regimen and review of the literature
    Brian H Kushner
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Cancer 119:665-71. 2013
    ..A major reason for using this regimen was the long time since patients received previous treatment with a platinum compound. The authors also summarized the published experience on ICE in patients with NB...
  4. ncbi request reprint Reduction from seven to five cycles of intensive induction chemotherapy in children with high-risk neuroblastoma
    Brian H Kushner
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    J Clin Oncol 22:4888-92. 2004
    ..We now describe similar results with changes that reduce toxicity (fewer cycles, less vincristine, use of granulocyte colony-stimulating factor)...
  5. ncbi request reprint A focal lesion in the falx cerebri: Harbinger of classic stage 4 neuroblastoma in an infant cured despite residual disease after minimal therapy
    Brian H Kushner
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Pediatr Blood Cancer 53:1340-2. 2009
    ..The falx cerebri probably does not represent an atypical site for stage 4S NB, but stage 4 NB with favorable biology is sometimes curable with minimal therapy...
  6. ncbi request reprint Camptothecin analogs (irinotecan or topotecan) plus high-dose cyclophosphamide as preparative regimens for antibody-based immunotherapy in resistant neuroblastoma
    Brian H Kushner
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Clin Cancer Res 10:84-7. 2004
    ..067 mg/kg was injected on day 1. With C/I, irinotecan, 50 mg/m(2) was infused i.v. (1 h) on days 1-5 (total, 250 mg/m(2)). Mesna and granulocyte colony-stimulating factor were used...
  7. ncbi request reprint Neuroblastoma in adolescents and adults: the Memorial Sloan-Kettering experience
    Brian H Kushner
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Med Pediatr Oncol 41:508-15. 2003
    ..We reviewed the utility of different treatment modalities in a large series of adolescents/adults with neuroblastoma (NB)...
  8. doi request reprint Differential impact of high-dose cyclophosphamide, topotecan, and vincristine in clinical subsets of patients with chemoresistant neuroblastoma
    Brian H Kushner
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Cancer 116:3054-60. 2010
    ....
  9. ncbi request reprint Curability of recurrent disseminated disease after surgery alone for local-regional neuroblastoma using intensive chemotherapy and anti-G(D2) immunotherapy
    Brian H Kushner
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    J Pediatr Hematol Oncol 25:515-9. 2003
    ..The authors report on a series of patients who had distant recurrences after surgery alone for local-regional neuroblastoma...
  10. ncbi request reprint Tumor lysis syndrome, neuroblastoma, and correlation between serum lactate dehydrogenase levels and MYCN-amplification
    Brian H Kushner
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, New York 10021, USA
    Med Pediatr Oncol 41:80-2. 2003
  11. doi request reprint High-dose cyclophosphamide-irinotecan-vincristine for primary refractory neuroblastoma
    Brian H Kushner
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Eur J Cancer 47:84-9. 2011
    ..We used a novel regimen for neuroblastoma (NB) that had responded inadequately to standard chemotherapy which now includes topotecan in induction or second-line therapy...
  12. doi request reprint High-dose carboplatin-irinotecan-temozolomide: treatment option for neuroblastoma resistant to topotecan
    Brian H Kushner
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Pediatr Blood Cancer 56:403-8. 2011
    ..We report a retrospective study of a novel regimen for neuroblastoma (NB) resistant to standard induction or salvage chemotherapy which now routinely includes topotecan...
  13. ncbi request reprint Neuroblastoma: a disease requiring a multitude of imaging studies
    Brian H Kushner
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Nucl Med 45:1172-88. 2004
    ..g., localized tumor), are likely to develop lethal metastatic disease, versus patients who have an ominous clinical profile (e.g., widespread disease) but are likely to survive, sometimes with little or no cytotoxic therapy...
  14. ncbi request reprint Treatment reduction for neuroblastoma
    Brian H Kushner
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, New York 10021, USA
    Pediatr Blood Cancer 43:619-21. 2004
  15. ncbi request reprint Induction for high-risk neuroblastoma
    Brian H Kushner
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, New York 10021, USA
    Pediatr Blood Cancer 49:221-3. 2007
  16. ncbi request reprint Irinotecan plus temozolomide for relapsed or refractory neuroblastoma
    Brian H Kushner
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 24:5271-6. 2006
    ..To report on an irinotecan and temozolomide regimen for neuroblastoma (NB). Quality of life and minimizing toxicity were major considerations...
  17. ncbi request reprint Ototoxicity from high-dose use of platinum compounds in patients with neuroblastoma
    Brian H Kushner
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 107:417-22. 2006
    ....
  18. ncbi request reprint High-dose cyclophosphamide inhibition of humoral immune response to murine monoclonal antibody 3F8 in neuroblastoma patients: broad implications for immunotherapy
    Brian H Kushner
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, New York 10021, USA
    Pediatr Blood Cancer 48:430-4. 2007
    ..We assessed the impact on rapid HAMA formation of prior chemotherapy in NB patients...
  19. ncbi request reprint Topotecan, thiotepa, and carboplatin for neuroblastoma: failure to prevent relapse in the central nervous system
    B H Kushner
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Bone Marrow Transplant 37:271-6. 2006
    ..Of eight patients transplanted in second or greater CR/VGPR, one became a long-term event-free survivor and seven relapsed though not in the CNS. This regimen has manageable toxicity but does not prevent CNS relapse...
  20. doi request reprint Reduced risk of secondary leukemia with fewer cycles of dose-intensive induction chemotherapy in patients with neuroblastoma
    Brian H Kushner
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Pediatr Blood Cancer 53:17-22. 2009
    ..We report a prospective study of secondary leukemia (SL)/myelodysplastic syndrome (MDS) in neuroblastoma (NB) patients treated with > or =5 cycles of dose-intensive chemotherapy...
  21. ncbi request reprint Liver involvement in neuroblastoma: the Memorial Sloan-Kettering Experience supports treatment reduction in young patients
    Brian H Kushner
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, New York 10021, USA
    Pediatr Blood Cancer 46:278-84. 2006
    ..We reviewed clinical and biologic findings in a series of infants with neuroblastoma (NB) in liver. The aim was to gain insights into improving therapy...
  22. pmc Sensitivity of surveillance studies for detecting asymptomatic and unsuspected relapse of high-risk neuroblastoma
    Brian H Kushner
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065, USA
    J Clin Oncol 27:1041-6. 2009
    ..Relapse-free survival (RFS) is a powerful measure of treatment efficacy. We describe the sensitivity of standard surveillance studies for detecting relapse of neuroblastoma (NB)...
  23. ncbi request reprint Five-day courses of irinotecan as palliative therapy for patients with neuroblastoma
    Brian H Kushner
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 103:858-62. 2005
    ..Quality of life was a major issue in choosing this regimen for patients whose disease was resistant to standard anti-NB therapies...
  24. doi request reprint Hyperfractionated low-dose (21 Gy) radiotherapy for cranial skeletal metastases in patients with high-risk neuroblastoma
    Brian H Kushner
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Int J Radiat Oncol Biol Phys 75:1181-6. 2009
    ..To present a large experience (73 patients) using a standard radiotherapy (RT) protocol to prevent relapse in cranial sites where measurable metastatic neuroblastoma (NB), an adverse prognostic marker, is common...
  25. ncbi request reprint High-dose carboplatin-irinotecan-temozolomide: Treatment option for neuroblastoma resistant to topotecan
    Brian H Kushner
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York
    Pediatr Blood Cancer 56:403-8. 2011
    ..We report a retrospective study of a novel regimen for neuroblastoma (NB) resistant to standard induction or salvage chemotherapy which now routinely includes topotecan...
  26. pmc Successful multifold dose escalation of anti-GD2 monoclonal antibody 3F8 in patients with neuroblastoma: a phase I study
    Brian H Kushner
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    J Clin Oncol 29:1168-74. 2011
    ..We hypothesized that 3F8 dose escalation is possible without increased analgesic requirements in patients pretreated with HM3F8...
  27. ncbi request reprint Chronic neuroblastoma
    Brian H Kushner
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 95:1366-75. 2002
    ..An indolent course is associated with neuroblastoma (NB) in adolescents and adults. In the current study, the authors analyzed this phenomenon in a large series of children with metastatic NB...
  28. ncbi request reprint High risk of leukemia after short-term dose-intensive chemotherapy in young patients with solid tumors
    B H Kushner
    Department of Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 16:3016-20. 1998
    ..To help fill the gap in knowledge about the risk of leukemia from repetitive high-dose use of alkylating agents and topoisomerase-II inhibitors in young patients with solid tumors...
  29. ncbi request reprint Neuroblastoma and treatment-related myelodysplasia/leukemia: the Memorial Sloan-Kettering experience and a literature review
    B H Kushner
    Department of Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 16:3880-9. 1998
    ..To assess treatment-related myelodysplasia/leukemia (t-AML) in neuroblastoma patients by a review of the Memorial Sloan-Kettering Cancer Center (MSKCC) data and the literature...
  30. ncbi request reprint Exploiting the MIBG-avidity of neuroblastoma for staging and treatment
    Brian H Kushner
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Pediatr Blood Cancer 47:863-4. 2006
  31. ncbi request reprint Clinically critical impact of molecular genetic studies in pediatric solid tumors
    B H Kushner
    Department of Human Genetics, Pathology, Pediatrics, and Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Med Pediatr Oncol 33:530-5. 1999
    ..We present cases depicting the importance of including molecular diagnostic studies in the routine evaluation of pediatric solid tumors...
  32. ncbi request reprint How effective is dose-intensive/myeloablative therapy against Ewing's sarcoma/primitive neuroectodermal tumor metastatic to bone or bone marrow? The Memorial Sloan-Kettering experience and a literature review
    B H Kushner
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 19:870-80. 2001
    ..We now present results achieved with that approach, as carried out at Memorial Sloan-Kettering Cancer Center (MSKCC) and as reported in the literature...
  33. ncbi request reprint Granulocyte-colony stimulating factor and multiple cycles of strongly myelosuppressive alkylator-based combination chemotherapy in children with neuroblastoma
    B H Kushner
    Department of Pediatrics and Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 89:2122-30. 2000
    ....
  34. ncbi request reprint Pilot study of topotecan and high-dose cyclophosphamide for resistant pediatric solid tumors
    B H Kushner
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Med Pediatr Oncol 35:468-74. 2000
    ..We tested the hypothesis that much higher dosing would meet critical goals of salvage therapy: antitumor effect and a lack of toxicity to key organs, so as not to preclude subsequent consolidative treatments needed for cure...
  35. ncbi request reprint Extending positron emission tomography scan utility to high-risk neuroblastoma: fluorine-18 fluorodeoxyglucose positron emission tomography as sole imaging modality in follow-up of patients
    B H Kushner
    Departments of Medical Imaging and Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Clin Oncol 19:3397-405. 2001
    ..We describe a role for PET in patients with neuroblastoma (NB)...
  36. ncbi request reprint Phase II trial of the anti-G(D2) monoclonal antibody 3F8 and granulocyte-macrophage colony-stimulating factor for neuroblastoma
    B H Kushner
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    J Clin Oncol 19:4189-94. 2001
    ..To describe oncolytic effects of treatment with anti-G(D2) monoclonal antibody 3F8 plus granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with neuroblastoma (NB)...
  37. ncbi request reprint Radically different treatment recommendations for newly diagnosed neuroblastoma: pitfalls in assessment of risk
    Brian H Kushner
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Pediatr Hematol Oncol 26:35-9. 2004
    ..Some patients classified as having high-risk neuroblastoma might actually do well with no cytotoxic therapy...
  38. ncbi request reprint N7: a novel multi-modality therapy of high risk neuroblastoma (NB) in children diagnosed over 1 year of age
    N K Cheung
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Med Pediatr Oncol 36:227-30. 2001
    ....
  39. ncbi request reprint Disaloganglioside GD2 loss following monoclonal antibody therapy is rare in neuroblastoma
    K Kramer
    Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA
    Med Pediatr Oncol 36:194-6. 2001
    ..CONCLUSIONS: The persistence of GD2 expression in refractory or recurrent NB suggests that complete antigen loss is an uncommon event and cannot account for treatment failure...
  40. ncbi request reprint Anti-G(D2) antibody treatment of minimal residual stage 4 neuroblastoma diagnosed at more than 1 year of age
    N K Cheung
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 16:3053-60. 1998
    ..To eradicate minimal residual disease with anti-G(D2) monoclonal antibody 3F8 in stage 4 neuroblastoma (NB) diagnosed at more than 1 year of age...
  41. ncbi request reprint High-dose melphalan with 6-hydroxydopamine-purged autologous bone marrow transplantation for poor-risk neuroblastoma
    B H Kushner
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York 10021
    Cancer 68:242-7. 1991
    ..In addition, the pattern of relapse in several patients could be explained by infusion of incompletely purged autografts; this would support recent laboratory evidence that 6-OHDA/ascorbate is a suboptimal purging method...
  42. ncbi request reprint Hyperfractionated low-dose radiotherapy for high-risk neuroblastoma after intensive chemotherapy and surgery
    B H Kushner
    Departments of Epidemiology and Biostatistics, Pediatrics, and Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY
    J Clin Oncol 19:2821-8. 2001
    ..Visible residual disease may warrant higher RT dosing. Patients with biologically unfavorable disease may be at increased risk for local failure. RT to the primary site may not be necessary when tumors are excised at diagnosis...
  43. ncbi request reprint Local control with multimodality therapy for stage 4 neuroblastoma
    S L Wolden
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Int J Radiat Oncol Biol Phys 46:969-74. 2000
    ..To evaluate the efficacy of 21 Gy hyperfractionated radiotherapy for local control in conjunction with surgery and intensive systemic therapy for patients with Stage 4 neuroblastoma...
  44. ncbi request reprint Detection of metastatic neuroblastoma in bone marrow: when is routine marrow histology insensitive?
    N K Cheung
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 15:2807-17. 1997
    ..To measure the sensitivity of histologic examination in detecting metastatic solid tumor in bone marrow...
  45. ncbi request reprint Topotecan combined with myeloablative doses of thiotepa and carboplatin for neuroblastoma, brain tumors, and other poor-risk solid tumors in children and young adults
    B H Kushner
    Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
    Bone Marrow Transplant 28:551-6. 2001
    ....
  46. ncbi request reprint Synovial sarcoma mimicking desmoplastic small round-cell tumor: critical role for molecular diagnosis
    P Cole
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Med Pediatr Oncol 32:97-101. 1999
    ..One alternative involves immunologic attack against markers derived from tumor-specific chromosomal defects such as those found in our patient...
  47. ncbi request reprint Detection of neuroblastoma in bone marrow by immunocytology: is a single marrow aspirate adequate?
    N K Cheung
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Med Pediatr Oncol 32:84-7. 1999
    ..We examined whether the chance of a positive IC from a single marrow site was comparable to an IC of pooled marrow from multiple sites...
  48. ncbi request reprint Oral etoposide for refractory and relapsed neuroblastoma
    B H Kushner
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 17:3221-5. 1999
    ..To describe the efficacy of oral etoposide against resistant stage 4 neuroblastoma...
  49. doi request reprint Hypothyroidism after 131I-monoclonal antibody treatment of neuroblastoma
    Sonal Bhandari
    Department of Pediatrics, New York Presbyterian Weill Cornell Medical College, New York, New York, USA
    Pediatr Blood Cancer 55:76-80. 2010
    ..To determine the prevalence of and risk factors for primary hypothyroidism following treatment with a radiolabeled monoclonal antibody ((131)I-3F8) in children with neuroblastoma...
  50. ncbi request reprint Clinical, pathologic, and molecular spectrum of tumors associated with t(11;22)(p13;q12): desmoplastic small round-cell tumor and its variants
    W L Gerald
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 16:3028-36. 1998
    ..We reviewed 109 cases of DSRCT to further characterize this entity better...
  51. ncbi request reprint The impact of gross total resection on local control and survival in high-risk neuroblastoma
    Michael P La Quaglia
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Pediatr Surg 39:412-7; discussion 412-7. 2004
    ..The authors reviewed their institutional experience to assess the effect of primary tumor resection on local control and overall survival...
  52. ncbi request reprint Effect of low-dose radiation therapy when combined with surgical resection for Ewing sarcoma
    T E Merchant
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Med Pediatr Oncol 33:65-70. 1999
    ..We retrospectively examined the clinical characteristics, treatment, and outcome for 25 patients with Ewing sarcoma treated with limited surgery and low-dose irradiation...
  53. ncbi request reprint Monoclonal antibody-based therapy of neuroblastoma
    N K Cheung
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Hematol Oncol Clin North Am 15:853-66. 2001
    ..Ongoing strategies to modify or reconstruct mAbs, to engage them with cytokines, or to unite them with T cells open new avenues for harnessing the unique forces of the immune system against some of the most deadly pediatric cancers...
  54. ncbi request reprint Recurrent metastatic neuroblastoma followed by myelodysplastic syndrome: possible leukemogenic role of temozolomide
    Brian H Kushner
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Pediatr Blood Cancer 51:552-4. 2008
    ..Salvage therapy featured 11 cycles of temozolomide. She developed myelodysplastic syndrome with 45,XX,der(7)t(7;21) (p15;q11),-21 at age 24 and refused treatment; 19 months later she was transfusion-dependent but her NB remained in CR...
  55. pmc Management and outcome of stage 3 neuroblastoma
    Shakeel Modak
    Department of Paediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Eur J Cancer 45:90-8. 2009
    ..We describe a single centre approach at Memorial Sloan-Kettering Cancer Centre (MSKCC) from 1991 to 2007 that minimises therapy except for those patients with MYCN-amplified NB...
  56. pmc Solitary relapse of desmoplastic small round cell tumor detected by positron emission tomography/computed tomography
    Brian H Kushner
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Clin Oncol 26:4995-6. 2008
  57. pmc Compartmental intrathecal radioimmunotherapy: results for treatment for metastatic CNS neuroblastoma
    Kim Kramer
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 429, New York, NY 10065, USA
    J Neurooncol 97:409-18. 2010
    ..The cRIT-salvage regimen for CNS metastases was well tolerated by young patients, despite their prior history of intensive cytotoxic therapies. It has the potential to increase survival with better than expected quality of life...
  58. ncbi request reprint Transient sialoadenitis: a complication of 131I-metaiodobenzylguanidine therapy
    Shakeel Modak
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Pediatr Blood Cancer 50:1271-3. 2008
    ..5] days. Serum lipase remained normal. Patients did not develop subsequent dry mouth or dysphagia...
  59. ncbi request reprint Quantitation of GD2 synthase mRNA by real-time reverse transcription-polymerase chain reaction: utility in bone marrow purging of neuroblastoma by anti-GD2 antibody 3F8
    Irene Y Cheung
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 94:3042-8. 2002
    ..Its utility in bone marrow (BM) purging is evaluated by a real-time reverse transcription-polymerase chain reaction (RT-PCR) assay to quantify the mRNA of GD2 synthase, the key enzyme in GD2 synthesis...
  60. ncbi request reprint Impact of metaiodobenzylguanidine scintigraphy on assessing response of high-risk neuroblastoma to dose-intensive induction chemotherapy
    Brian H Kushner
    Departments of Medical Imaging and Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 21:1082-6. 2003
    ..We present the first report on the effect of MIBG scans on the classification of response to dose-intensive induction therapy...
  61. ncbi request reprint Quantitation of GD2 synthase mRNA by real-time reverse transcriptase polymerase chain reaction: clinical utility in evaluating adjuvant therapy in neuroblastoma
    Irene Y Cheung
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 21:1087-93. 2003
    ..Because therapy (myeloablation, immunotherapy, or differentiation) for MRD is applied at the time of clinical remission, objective surrogate markers are needed to gauge treatment efficacy...
  62. ncbi request reprint Oral topotecan for refractory and relapsed neuroblastoma: a retrospective analysis
    Kim Kramer
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Pediatr Hematol Oncol 25:601-5. 2003
    ..Although toxicity was generally thought to be mild, the efficacy of such an approach remains unproven...
  63. ncbi request reprint Long-term event-free survival after intensive chemotherapy for Ewing's family of tumors in children and young adults
    E Anders Kolb
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, PO Box 139, 1275 York Ave, New York, NY 10021, USA
    J Clin Oncol 21:3423-30. 2003
    ..To improve the long-term event-free survival of patients with Ewing's family of tumors (EFTs) using high-dose, short-term chemotherapy...
  64. ncbi request reprint Early molecular response of marrow disease to biologic therapy is highly prognostic in neuroblastoma
    Irene Y Cheung
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 21:3853-8. 2003
    ..To use early marrow response as a prognostic marker is particularly relevant for patients not likely to benefit from this therapy...
  65. doi request reprint Whole neuraxis irradiation to address central nervous system relapse in high-risk neuroblastoma
    Victoria J Croog
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Int J Radiat Oncol Biol Phys 78:849-54. 2010
    ..This study describes the use of craniospinal irradiation (CSI) for CNS relapse and compares outcomes to patients who received focal radiotherapy (RT)...
  66. ncbi request reprint Brain-sparing radiotherapy for neuroblastoma skull metastases
    Suzanne L Wolden
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Pediatr Blood Cancer 50:1163-8. 2008
    ..The purpose of this study was to describe the technique, outcome and toxicities in patients with high risk NB metastatic to the skull treated with brain-sparing skull radiotherapy (BSRT)...
  67. ncbi request reprint FCGR2A polymorphism is correlated with clinical outcome after immunotherapy of neuroblastoma with anti-GD2 antibody and granulocyte macrophage colony-stimulating factor
    Nai Kong V Cheung
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 24:2885-90. 2006
    ..Granulocyte macrophage colony-stimulating factor (GM-CSF) enhances phagocyte-mediated ADCC. The differential affinity of the human FCGR polymorphic alleles for 3F8 may influence the effectiveness of antibody immunotherapy...
  68. ncbi request reprint Long-term complications in survivors of advanced stage neuroblastoma
    Caroline Laverdiere
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Pediatr Blood Cancer 45:324-32. 2005
    ..Few studies have assessed late effects in neuroblastoma (NB) survivors, particularly those with advanced stage disease...
  69. ncbi request reprint Favorable-biology neuroblastoma presenting with leptomeningeal metastases?: a case presentation
    Kim Kramer
    Department of Pediatrics, Sloan Kettering Cancer Center, New York, New York, USA
    J Pediatr Hematol Oncol 26:703-5. 2004
    ..This case illustrates that some infants with favorable-biology neuroblastoma may be observed without treatment despite the advanced INSS stage...
  70. ncbi request reprint Neuroblastoma--from genetic profiles to clinical challenge
    Brian H Kushner
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, USA
    N Engl J Med 353:2215-7. 2005
  71. ncbi request reprint Treatment of spinal involvement in neuroblastoma patients
    David I Sandberg
    Department of Surgery, Division of Neurosurgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, N Y 10021, USA
    Pediatr Neurosurg 39:291-8. 2003
    ..Considerable controversy exists regarding the appropriate management of spinal involvement in neuroblastoma (NB) patients. We review a large group of such patients and offer treatment recommendations...
  72. ncbi request reprint Whole abdominopelvic radiotherapy for desmoplastic small round-cell tumor
    Karyn A Goodman
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Int J Radiat Oncol Biol Phys 54:170-6. 2002
    ..Our objective was to evaluate the feasibility and outcome of whole abdominopelvic irradiation (WAPI) as part of a combined modality protocol for patients with DSRCT...
  73. ncbi request reprint Should we replace bone scintigraphy plus CT with MR imaging for staging of neuroblastoma?
    Nai Kong V Cheung
    Radiology 226:286-7; author reply 287-8. 2003
  74. ncbi request reprint Risks outweighed benefits from local radiation for non-stage 4 neuroblastoma
    Nai Kong V Cheung
    Int J Radiat Oncol Biol Phys 54:1575; author reply 1575. 2002
  75. doi request reprint Neuroblastoma--linking a common allele to a rare disease
    Brian H Kushner
    N Engl J Med 358:2635-7. 2008